Insulet Co. (NASDAQ:PODD) Stock Holdings Lessened by Bridgewater Associates LP

Bridgewater Associates LP lessened its holdings in shares of Insulet Co. (NASDAQ:PODD) by 30.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,730 shares of the medical instruments supplier’s stock after selling 3,412 shares during the period. Bridgewater Associates LP’s holdings in Insulet were worth $2,018,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Baillie Gifford & Co. raised its position in shares of Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares during the period. Geode Capital Management LLC grew its stake in Insulet by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier’s stock worth $463,347,000 after buying an additional 40,566 shares during the last quarter. Norges Bank acquired a new stake in Insulet in the fourth quarter worth $248,806,000. Artisan Partners Limited Partnership lifted its stake in Insulet by 24.1% in the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock valued at $201,073,000 after buying an additional 149,524 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Insulet by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock valued at $168,902,000 after acquiring an additional 10,694 shares during the period.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Insulet Trading Down 1.6 %

Shares of NASDAQ:PODD opened at $246.80 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a market capitalization of $17.33 billion, a price-to-earnings ratio of 42.63, a PEG ratio of 3.62 and a beta of 1.30. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a 50 day moving average price of $263.29 and a 200 day moving average price of $260.80.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, research analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on PODD shares. Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Raymond James reaffirmed an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Wells Fargo & Company boosted their price target on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.